Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG

Open source

DOI: 10.1182/blood-2015-05-643320
Published: 2015 Nov 12
Container: Blood
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood-2015-05-643320,
  title = {Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.},
  author = {Shah JJ and Stadtmauer EA and Abonour R and Cohen AD and Bensinger WI and Gasparetto C and Kaufman JL and Lentzsch S and Vogl DT and Gomes CL and Pascucci N and Smith DD and Orlowski RZ and Durie BG},
  year = {2015},
  journal = {Blood},
  doi = {10.1182/blood-2015-05-643320},
  url = {https://doi.org/10.1182/blood-2015-05-643320}
}

RIS

TY  - JOUR
TI  - Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
AU  - Shah JJ
AU  - Stadtmauer EA
AU  - Abonour R
AU  - Cohen AD
AU  - Bensinger WI
AU  - Gasparetto C
AU  - Kaufman JL
AU  - Lentzsch S
AU  - Vogl DT
AU  - Gomes CL
AU  - Pascucci N
AU  - Smith DD
AU  - Orlowski RZ
AU  - Durie BG
PY  - 2015
JO  - Blood
DO  - 10.1182/blood-2015-05-643320
UR  - https://doi.org/10.1182/blood-2015-05-643320
ER  -

APA

JJ, S., EA, S., R, A., AD, C., WI, B., C, G., JL, K., S, L., DT, V., CL, G., N, P., DD, S., RZ, O., & BG, D. (2015). Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.. Blood. https://doi.org/10.1182/blood-2015-05-643320

Source records

pubmed · retrieved 2026-09-27T07:09:14.215Z